“Gorlin Syndrome Beyond PTCH1 and SUFU: Leave No Patients Undiagnosed”
Barbara Rivera Polo, PhD, Principal Investigator and Miguel Servet Fellow at the Rare Tumors Lab – Hereditary Cancer Programme with the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain.
2024
“Defining the BCC microenvironment change in response to smoothened inhibition: Identification of a role for addition of checkpoint inhibitor to optimize antitumor therapy for overwhelming disease.”
Dr. John Carucci, NYU Grossman School of Medicine
2023
“Clinical Practice Guidelines for the Management of Basal Cell Carcinoma in Gorlin Syndrome.”
Murad Alam, MD, Northwestern University Feinberg School of Medicine
Co-Investigator:Dr. Cahn, PGY-3 Resident in the Department of Dermatology, University of Illinois, Chicago.
.jpg?width=250&name=1578553822%20(1).jpg "1578553822 (1)")
%20(2).png?width=150&height=64&name=GSA%20Logo%20High%20Res%20No%20Background%20(1)%20(2).png)
%20(2)-1.png?width=200&height=85&name=GSA%20Logo%20High%20Res%20No%20Background%20(1)%20(2)-1.png)